Transcription of Aml1/eto in Bone Marrow and Cord Blood of Individuals without Acute Myelogenous Leukemia
J. Basecke,L. Cepek,C. Mannhalter,J. Krauter,Stefanie Hildenhagen,G. Brittinger,L. Trumper,F. Griesinger
Abstract:these last often engaged in hemophagocytosis. 1,2 The central nervous system (CNS) is variably involved, with symptoms that range from irritability, bulging fontanel, and neck stiffness to seizures, cranial nerve palsies, ataxia, psychomotor retardation, and coma. Markedly different presenting pictures are not described in the available series. 1,5 Adult onset of familial HLH, never reported before, is the most prominent feature in this family. Their presenting features were different, with a prominent CNS involvement 9 in one case and a diagnosis of non-Hodgkin lymphoma (NHL) in the other. Remarkably , in both cases the final diagnosis was delayed by about 3 years from the onset of symptoms; both achieved an adequate disease control when treated and did not show disease reactivation for more than one year after the diagnosis. Given the limited potential for antiviral defense in patients with PRF1 mutations, 10 the prolonged absence of clinical manifestations due to macrophage activation following common viral infections in these subjects is unexpected. In case 2 the diagnosis of NHL led to polychemotherapy followed by autologous BMT. Her prolonged remission is also unexpected, as an autologous BMT consolidation has no potential to restore the genetically determined immune deficiency of the patient. We have previously observed in one HLH patient, after acute graft rejection, an 18-month disease-free interval before overt disease reactivation (M.A. and F.L., unpublished observation, 1998). The mechanism by which massive immune suppression associated with the pre-BMT conditioning regimen may result in a prolonged disease control remains to be elucidated. Even in the presence of quite different clinical presentations, both patients carried the same mutations. The Trp374Stop mutation has been previously reported in 9 patients always as a homozygous mutation. All these patients showed a homogeneous phenotype with a severe clinical course and an early age of onset, within the first months of life in 8 of 9 cases, with the ninth presenting at 39 months. This mutation was always found in subjects of Turkish origin; historical data are available that may support the hypothesis of migration of the mutation from Turkey to southern Italy in ancient times. Further research will clarify whether this mutation originated in the same haplotype both in the Italian and Turkish population. We confirm that Trp374Stop appears to be the most frequently reported mutation in HLH and suggest that Ala91Val (which we found also in 4 other Italian patients; Clementi et al, in preparation) may be …